Bioanalytical Method Validation Summary — GLPI-103 (PK Assay & Anti-Drug-Antibody Assay)
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The validation of the PK (LC–MS/MS) assay and the tiered anti-drug-antibody assay to ICH M10.
Why it exists. Every PK and immunogenicity number is only as trustworthy as the assay that produced it. This documents the accuracy, precision, selectivity, stability, and (for PK) incurred-sample reanalysis that make the CLINPHARM and IMMUNO conclusions defensible.
How it is produced here. It is a clinical-pharmacology study report. Because this portfolio simulates only the Phase 3 clinical dataset, the PK/PD, immunogenicity, and assay values here are deep-knowledge mock — realistic, standard-conformant numbers that stand in for the individual clin-pharm study reports, kept consistent with the trial's pharmacology and the Investigator's Brochure.
Format & governing standard. —
Bioanalytical Method Validation Summary — GLPI-103 (PK Assay & Anti-Drug-Antibody Assay)
| Field | Value |
|---|---|
| Document ID | BIOANALYTICAL-001 |
| Version | 1.0 |
| Status | Final |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| CTD location | Module 5.3.1.4 / 2.7.1 — Bioanalytical & analytical methods |
| Standard(s) | ICH M10 (Bioanalytical Method Validation); FDA/EMA BMV guidance |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No bioanalytical dataset is simulated. Validation parameters are illustrative and consistent with ICH M10 acceptance criteria for a peptide LC–MS/MS assay and a ligand-binding ADA assay. This document stands in for the full method-validation reports a real submission would file, and supports the PK (CLINPHARM-002) and immunogenicity (IMMUNO-001) analyses.
Change History
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-07-05 | Bioanalytical | Initial submission-grade summary of PK-assay and ADA-assay validation |
Abbreviations
ADA anti-drug antibody · CV coefficient of variation · ISR incurred-sample reanalysis · LC–MS/MS liquid chromatography–tandem mass spectrometry · LLOQ lower limit of quantification · MRD minimum required dilution · QC quality control · ULOQ upper limit of quantification.
1. Scope
Two validated methods underpin the clinical-pharmacology and immunogenicity programs: (1) a quantitative LC–MS/MS assay for GLPI-103 in human plasma (PK), and (2) a tiered ligand-binding ADA assay (screening/confirmatory/titre/neutralizing). Both were validated to ICH M10 prior to sample analysis and monitored by in-study QC and, for the PK assay, incurred-sample reanalysis.
2. PK Assay — LC–MS/MS (human plasma) [MOCK]
| Validation parameter | Result | ICH M10 acceptance |
|---|---|---|
| Analyte / internal standard | GLPI-103 / stable-isotope-labelled GLPI-103 | — |
| Calibration range (LLOQ–ULOQ) | linear over the clinical range | ≥ 75% calibrators within ±15% (±20% at LLOQ) |
| Accuracy (QC, inter-run) | within ±15% of nominal (±20% at LLOQ) | ±15% / ±20% |
| Precision (QC, inter-run CV) | ≤ 15% (≤ 20% at LLOQ) | ≤ 15% / ≤ 20% |
| Selectivity / specificity | no interference from matrix, metabolites, or co-medications (metformin, semaglutide) | met |
| Matrix effect / recovery | consistent, reproducible | met |
| Stability | bench-top, freeze–thaw, long-term frozen, autosampler — all covered | met |
| Dilution integrity | validated for above-ULOQ samples | met |
| Incurred-sample reanalysis (ISR) | ≥ 2/3 of samples within 20% | ≥ 67% within 20% |
The PK assay met all ICH M10 criteria and was fit for purpose for the pharmacokinetic analyses (CLINPHARM-002).
3. Anti-Drug-Antibody Assay — tiered ligand-binding [MOCK]
| Validation parameter | Result | Basis |
|---|---|---|
| Format | bridging electrochemiluminescence immunoassay | — |
| Screening cut point | statistically determined (target ~5% false-positive) | FDA/EMA immunogenicity guidance |
| Confirmatory cut point | competitive inhibition with excess drug (~1% false-positive) | — |
| Sensitivity | low-ng/mL surrogate positive control | fit-for-purpose |
| Drug tolerance | adequate at anticipated trough drug concentrations | — |
| Minimum required dilution (MRD) | established | — |
| Titre & neutralizing (NAb) | serial-dilution titre; competitive ligand-binding NAb | characterization tiers |
| Selectivity / matrix | no relevant interference | — |
The tiered ADA method met fit-for-purpose validation criteria and supported the integrated immunogenicity assessment (IMMUNO-001), including drug-tolerance adequate to interpret on-treatment samples and a NAb assay to characterize positive samples.
4. Conclusion
Both bioanalytical methods were validated to ICH M10 and monitored during sample analysis (in-study QC; PK ISR), establishing that the pharmacokinetic and immunogenicity conclusions rest on analytically sound data. Method details and validation are cross-referenced from Module 2.7.1 and the individual PK/immunogenicity reports.
5. References
ICH M10; FDA/EMA bioanalytical and immunogenicity guidance; CLINPHARM-002 (PK); IMMUNO-001 (immunogenicity); M2.7.1.
Comments (0)
No comments yet. Be the first to say something!